Acrotussin

Quick links to important sections

Acrotussin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acrotussin

Property Description
Active ingredient Chlorpheniramine, Dextromethorphan Hydrobromide
Form Oral Liquid, Syrup
Pharmacological class Combination Antihistamine and Antitussive
Common use Symptomatic relief of cough and allergy symptoms
Origin Synthetic

Acrotussin: Definition and Type of Combination Medicine

Acrotussin is fundamentally a fixed-dose combination product, typically provided as an oral liquid or syrup, classified as a multi-symptom relief medication. This structure incorporates two distinct active ingredients into a singular formulation, establishing its identity as a convenient approach to managing complex respiratory symptoms associated with the common cold or seasonal allergic rhinitis symptoms. Fixed-dose combinations are used to treat multiple symptoms concurrently, simplifying the patient's treatment regimen.

Composition and Pharmacological Classification

The medication is composed of two primary synthetic active ingredients: Chlorpheniramine maleate and Dextromethorphan Hydrobromide. Acrotussin is classified based on these components as a combination of an Antihistamine and an Antitussive. Chlorpheniramine functions as a first-generation antihistamine that targets the body's allergic response. Dextromethorphan is a non-narcotic agent that serves as a cough suppressant, categorized as a morphinan derivative. Chlorpheniramine is recognized for effectively blocking histamine receptors, thereby helping to control sneezing and nasal discharge.

General Therapeutic Purpose of the Dual-Action Formulation

The general purpose of Acrotussin is to provide comprehensive symptomatic treatment by simultaneously addressing both the irritating triggers and the resulting symptoms of an illness. The antihistamine component helps to relieve symptoms like sneezing and runny nose (rhinorrhea), while the antitussive component provides relief from a persistent, non-productive cough. This strategic, two-pronged action facilitates comfort and helps manage the acute, irritating symptoms arising from upper respiratory tract illnesses.

Regulatory References

  1. Chlorpheniramine (MedlinePlus)

What side effects are possible with Acrotussin?

Possible Side Effects and Safety Information

The safety profile of Acrotussin (Chlorpheniramine/Dextromethorphan) is officially organized based on the frequency and the physiological system affected, reflecting data from regulatory documents.


Adverse Reaction Classification

The most frequently documented side effects are categorized as Common, primarily involving the Nervous System and Gastrointestinal Disorders. Reactions are grouped by the physiological system affected according to regulatory standards.

Frequency Classification Examples of Documented Reactions
Common Drowsiness, sedation, dry mouth, nausea, vomiting
Uncommon Nervousness, dizziness, headache, blurred vision, urinary retention
Rare Blood dyscrasias, severe cardiovascular events (e.g., arrhythmias), anaphylaxis

Drowsiness and sedation are generally noted as more likely and prominent at the start of therapy, consistent with the established safety patterns of first-generation antihistamines. Uncommon effects on the Eye Disorders system include visual disturbances.


Safety Considerations and Restrictions

Official regulatory documents mandate specific safety considerations for certain patient groups. Older adults may have an increased risk of Central Nervous System effects, such as confusion and sedation. Children have the documented potential for paradoxical excitability rather than sedation. Caution is typically required in individuals with hepatic impairment.

High-level safety constraints include the contraindication against concurrent use with Monoamine Oxidase Inhibitors (MAOIs), due to the potential risk of a serious systemic reaction. Use is also restricted in individuals with conditions such as narrow-angle glaucoma or prostatic hypertrophy, due to potential exacerbation by anticholinergic effects.

Overdose and Emergency Response

The official regulatory documentation for Acrotussin overdose outlines a serious clinical presentation due to the combined effects of its components. Symptoms are categorized by significant effects on the Central Nervous System (CNS), which can manifest as either profound CNS depression leading to lethargy and potentially coma, or, paradoxically, as CNS stimulation, including agitation, hallucinations, and seizures. The antihistamine component also contributes to signs of Anticholinergic Syndrome, such as high fever (hyperpyrexia), difficulty urinating (urinary retention), and widely dilated pupils.

Acrotussin overdose carries the risk of severe, life-threatening outcomes. These include respiratory depression, cardiovascular collapse, and the potential development of Serotonin Syndrome, which is explicitly documented as a complication. Due to these critical risks, government regulatory agencies mandate that individuals seek immediate medical attention and contact emergency services for any suspected overdose.

No specific antidote is known for the combination product. Treatment procedures officially described include comprehensive symptomatic and supportive treatment, gastric lavage, or administration of activated charcoal to limit absorption. Hospital monitoring is required, including cardiovascular monitoring and observation for at least 24 hours. Children and elderly patients are noted as having increased susceptibility to severe CNS and anticholinergic manifestations.

Therapeutic Uses of Acrotussin

What Acrotussin Treats: Main Uses and Benefits

The medication is generally applied across domains where additional symptomatic support is needed, specifically for the common cold and upper respiratory allergies. Acrotussin is commonly used in areas where short-term symptom management is appropriate.

This combination is relevant in situations involving recurrent or episodic manifestations such as hay fever and acute viral cold episodes. The relevant therapeutic areas include symptomatic relief for the common cold, management of dry, irritative cough, and easing allergic manifestations. This approach is used for managing symptom clusters, which may contribute to improved comfort during periods of heightened symptoms.


“This formulation is commonly used when symptoms cluster into patterns requiring supportive management, focusing on both the cough reflex and allergic distress.”


Support for Dual Symptom Domains

This medication is used across domains where additional symptomatic support is needed, often when groups of symptoms appear suddenly or fluctuate, such as a cough alongside allergy manifestations. This dual approach is relevant when supportive symptom management is appropriate, which may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Concurrent Cough and Allergy Symptoms

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Who Can and Cannot Use Acrotussin?

Acrotussin is authorized for use primarily in adults and adolescents (typically 12 years of age and older). Eligibility is strictly defined by regulatory documents, focusing on absolute contraindications and population-specific restrictions.

The medicine is contraindicated and must not be used by patients who have a known hypersensitivity to its active components, or by individuals who are currently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. Use is also prohibited in newborns and premature infants.

Specific comorbidities prohibit use, including closed-angle glaucoma, symptomatic prostatic hypertrophy, bladder neck obstruction, and severe cardiovascular disease.

Regarding age, Acrotussin is typically contraindicated in children under 2 years, and often not recommended for those under 4 or 6 years. Older adults require cautious use due to increased sensitivity. Furthermore, use is not recommended during pregnancy (especially the third trimester) and lactation. Patients with conditions such as hepatic or renal impairment must also use the medicine with caution.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section outlines officially documented drug-drug and drug-substance interactions for Acrotussin (Chlorpheniramine and Dextromethorphan) as stated in regulatory prescribing information.

Contraindicated Combinations

The co-administration of Acrotussin is strictly prohibited with Monoamine Oxidase Inhibitors (MAOIs), including Isocarboxazid, Phenelzine, Linezolid, and Selegiline. A mandatory 14-day washout period is required after stopping MAOI therapy before starting Acrotussin, due to the risk of severe pharmacodynamic effects.


Documented Interaction Categories

Interaction Type Interacting Substance/Class Regulatory Requirement/Effect
Pharmacodynamic CNS Depressants & Alcohol May result in additive CNS depression, increasing drowsiness and impaired coordination.
Pharmacokinetic CYP2D6 Inhibitors (e.g., Quinidine) May increase Dextromethorphan plasma levels and exposure due to inhibition of metabolism.
Serotonergic Risk SSRIs & St. John's Wort Official risk of Serotonin Syndrome due to the additive serotonergic effect of Dextromethorphan.

Population-Specific Cautions

Official prescribing information notes that elderly patients (60 years and older) may be more susceptible to adverse reactions and interactions. Patients with pre-existing hepatic or renal impairment may also face a heightened risk of interaction severity due to accumulation of the drug and its metabolites.

Mechanism of Action

Central Receptor Modulation of Efferent Pathway Excitability

Acrotussin modulates signaling sequences associated with specific physiological responses within the central nervous system. It primarily affects systems where specific transmitters or mediators dominate, binding to sites within the brainstem to increase the stimulus intensity required for receptor activation within the medullary cough center. This mechanistic cascade initiates molecular steps that alter the excitability of efferent pathways, thereby reducing the probability of successive reflex activation.


Modulation of Respiratory Secretion Viscoelasticity

The drug acts within domains involving localized biochemical and cellular signaling in the respiratory tract. It modifies early molecular steps that shape systemic physiological outcomes, leading to augmented transepithelial water transport and altered viscoelastic properties of respiratory secretions. This action decreases the concentration of mediators responsible for localized fluid retention and induces changes in ion channel activity that modify the epithelial fluid layer, resulting in reduced adhesiveness and increased mobility of the mucociliary layer.

Dosage and Administration Information

How to Use Acrotussin

Acrotussin, a combination containing Chlorpheniramine Maleate and Dextromethorphan Hydrobromide, is administered via the oral route as a liquid or tablet to manage acute symptoms. Its use is defined by a standardized, intermittent dosing schedule, intended for temporary, as-needed relief rather than continuous or long-term therapy.


Official Dosing and Frequency

Administration follows a strict 24-hour dose limit, with the dosing interval set at 6 hours. The liquid form requires using the special dosing device provided with the product to ensure accurate measurement.

Age Group Single Dose Maximum Daily Limit Dosing Interval
Adults (12+ years) 20 mL (Liquid) or 1 Tablet 4 Doses in 24 hours Every 6 hours
Children (6 to <12 years) 10 mL (Liquid) 4 Doses in 24 hours Every 6 hours
Children (<6 years) Not Labeled for Use - -

Administration Logistics and Duration

The oral suspension must be shaken well before each dose to ensure the medication is properly mixed. The medicine may be taken with or without food, according to patient preference.

The usage protocol specifies that the medicine should be used for a short duration, generally not to exceed seven days for self-treatment. If a dose is missed, the user should skip the missed dose if the next dose is due soon and never take a double dose to make up for it. Adherence to the stated maximum daily dose and duration is necessary.

Recent Clinical Evidence

Evidence for Acute Cough and Cold Symptoms

The research landscape for Acrotussin (a combination of Chlorpheniramine and Dextromethorphan) has explored its use for the symptomatic management of acute cough and associated cold-related discomfort. Studies include short-term Randomized Controlled Trials (RCTs) focusing on the individual active components, as well as systematic reviews of the broader drug class. Research primarily measures patient-reported outcomes over defined intervals, typically 3 to 7 days. Findings describe patterns observed in the studies, but the certainty regarding the specific fixed-dose combination remains low in this setting. Trials for acute cough and cold commonly observe a notable placebo effect, which is reflected in the evidence base.


Evidence for Cough Associated with Allergic Rhinitis

This section of the evidence explores how the dual-action medicine was studied for the symptomatic management of unproductive cough that occurs alongside allergic manifestations. The available evidence includes data from Post-Marketing Surveillance Studies and smaller, open-label studies. The foundational evidence includes controlled trials that have examined the antihistamine component (Chlorpheniramine) in treating general allergic manifestations. Certainty remains low for the combination product itself, as much of the evidence for the allergy component is derived from studies of Chlorpheniramine as a single agent.


Research Gaps and Limitations

The main research exploring how symptoms change over time has focused predominantly on otherwise healthy adults experiencing acute symptoms. Data for certain groups remain insufficient; few dedicated controlled data are available for special populations such as children or older adults. Consequently, long-term effects are not fully established, and follow-up durations were limited. A key limitation is that comparative evidence is lacking between the specific combination product and its individual components administered separately. This highlights areas where more dedicated, large-scale controlled trials are needed.

Key Studies & References

  1. Label: COUGH AND COLD HBP- chlorpheniramine maleate, dextromethorphan hbr tablet, film coated (A representative combination regulatory document)
  2. Chlorpheniramine: MedlinePlus Drug Information (NIH/NLM)

Frequently Asked Questions (FAQ)

Common questions about Acrotussin (FAQ)


Q: What should I do if I accidentally take two doses of Acrotussin too close together?

Regulatory information indicates that there is an increased risk of accidental overdose if products containing similar active ingredients are taken too close together or combined. In the event of a suspected overdose, contacting a poison control center or seeking emergency medical help is the mandated course of action.


Q: Can Acrotussin be taken at the same time as other pain relievers (like acetaminophen)?

Official drug interaction summaries suggest that the active components in this medicine can generally be taken alongside common over-the-counter pain relievers, such as acetaminophen or ibuprofen. However, reviewing the labels of all medicines used is generally recommended to prevent doubling up on the same active ingredients.


Q: Does Acrotussin interact with medications for high blood pressure?

Product warnings advise that patients with high blood pressure or heart disease should consult a healthcare provider before using the medicine. This is because the antihistamine component can potentially affect individuals with pre-existing cardiovascular conditions.


Q: Is Acrotussin suitable for individuals with kidney or liver issues?

Official regulatory documents advise consulting a healthcare provider before use if a patient has liver disease. This caution is noted because hepatic (liver) or renal (kidney) impairment may result in a heightened risk of adverse reaction severity due to the way the body processes the medication.


Q: Why do some cough medicines cause stomach upset, and is Acrotussin one of them?

The most frequently documented reactions related to the antitussive (cough suppressant) component include nausea and gastrointestinal discomfort. Nausea and vomiting are listed among the common side effects of the product.


Q: Does Acrotussin help with chest congestion or only a dry cough?

The medication's cough suppressant is intended primarily for a non-productive cough (a dry cough) caused by minor irritation. Regulatory warnings indicate that consultation with a healthcare provider is recommended before using the product if a person has a cough that involves excessive phlegm or mucus (chest congestion).


Q: How does the action of Acrotussin differ from that of a common decongestant?

Acrotussin is classified as a combination of an antihistamine and a cough suppressant, which address allergic symptoms and the urge to cough. A common decongestant, by contrast, is a different class of medicine that works specifically by constricting blood vessels to reduce swelling in the nasal passages.


Q: Is Acrotussin available without a prescription, or does it require one?

According to authoritative sources, the combination of active ingredients in Acrotussin is typically categorized and available as an Over-the-Counter (OTC) medication for temporary relief of acute symptoms.


Q: How long does it typically take for Acrotussin to start working?

Official pharmacology information indicates that relief from symptoms may begin to be experienced approximately 15 to 30 minutes after a single dose has been administered.


Q: What is the expected duration of effect after a single dose of Acrotussin?

The cough suppressant component, Dextromethorphan, has a reported duration of action that can range from 3 to 8 hours in the body, which dictates the required dosing interval.


Q: Is it normal to feel nauseous after taking Acrotussin?

Yes, according to official safety profile documents, nausea and vomiting are listed as commonly documented side effects. These effects are often associated with the cough suppressant component.


Q: Do side effects from Acrotussin usually go away on their own?

Reports suggest that most documented side effects, including central nervous system (CNS) and gastrointestinal (GI) issues, typically resolve within a day after the final dose is taken.


Q: Are there any signs of a serious side effect related to Acrotussin that require attention?

Official labels advise stopping use and consulting a doctor if the cough persists longer than one week or is accompanied by specific symptoms. These include a fever, a rash, or a persistent headache, as these may indicate a more serious condition.


Q: Are there known food or drink interactions with Acrotussin?

Regulatory documentation notes that consuming grapefruit juice may potentially increase the concentrations and exposure of the cough suppressant component in the body. It is important to review the product label for any additional instructions regarding food and drink.


Q: Can Acrotussin be taken with commonly used dietary supplements or herbal products?

The product label advises consulting a healthcare provider or pharmacist before use when taking herbal products or supplements. This is especially true for any product that may have a serotonergic effect, such as St. John’s Wort.


Q: Can individuals with a history of asthma or COPD use Acrotussin?

Regulatory warnings advise consulting a doctor before using the product if a patient has a breathing problem such as emphysema, chronic bronchitis, or persistent cough associated with asthma. The medicine is not officially recommended for a chronic persistent cough.


Q: Is Acrotussin considered a sedative or non-drowsy cough relief option?

The product label explicitly warns that marked drowsiness may occur. This is consistent with the antihistamine component being a first-generation type, which is known for its potential to cause sedation.


Q: Is Acrotussin the same as other cough brands like Robitussin or Mucinex?

Acrotussin is a fixed-dose combination product containing two active ingredients that are common in cough and cold remedies. These same active ingredients can be found in a variety of other brand-name and generic products intended for similar symptomatic relief.


Q: How quickly should the cough improve after starting Acrotussin?

Acrotussin is intended only for temporary relief of acute symptoms. Official guidance notes that if the cough symptom worsens or persists for more than seven days, the medicine should be discontinued, and a healthcare professional consulted.


Q: What official information is available about long-term use of Acrotussin?

Official guidance strictly mandates that this medicine is intended for temporary relief only. It should not be used for a cough that persists or tends to recur for more than one week.


Q: Are there specific warnings related to taking Acrotussin before driving or operating machinery?

The regulatory label explicitly advises users to use caution when driving a motor vehicle or operating heavy machinery. This warning is mandated due to the known possibility of marked drowsiness associated with the medication.


Q: What is the clinical trial evidence basis for Acrotussin’s effectiveness?

The evidence basis for this drug class includes short-term Randomized Controlled Trials (RCTs) focusing on the individual active components to assess symptomatic relief. Evidence certainty for the specific fixed-dose combination often remains low in this setting.


Q: What patient groups were included in the primary studies for Acrotussin?

Primary studies used to assess this class of cough and cold drugs have predominantly enrolled adults. Dedicated controlled data for special populations, such as children and older adults, remain insufficient in the evidence base.


Q: Why is Acrotussin not recommended for a cough accompanied by a fever?

Official labeling advises stopping use and consulting a doctor if the cough is accompanied by a fever. This is because the combination of these symptoms could be a sign of a more serious underlying condition that requires specific medical attention.


Q: Is there a non-sugar or diabetic-friendly version of Acrotussin available?

Some products containing similar active ingredients are formulated as 'Sugar Free' or use alternative sweeteners. It is recommended to check the ingredients list for specific product formulations to meet dietary needs.


Q: Does Acrotussin contain any ingredients that affect blood sugar levels?

The label advises consulting a doctor before use if a patient has diabetes. While the product is generally considered safe at recommended doses, the cough suppressant component's potential influence on blood glucose has been investigated in research.


Q: Are there specific health conditions that make a person ineligible to use Acrotussin?

Yes, regulatory documents list specific conditions where use is contraindicated or requires prior consultation. These include conditions such as closed-angle glaucoma, enlargement of the prostate gland, and difficulty with urination.


Q: Does the product label for Acrotussin contain any ingredients that may cause jitteriness or insomnia?

The label notes that nervousness or sleeplessness (insomnia) may occur as possible side effects. The potential for excitability or paradoxical stimulation is also specifically noted, particularly in the pediatric population.

How should Acrotussin be stored and disposed of?

Storage and Disposal Conditions for Acrotussin

The storage and disposal instructions for Acrotussin (Chlorpheniramine/Dextromethorphan Oral Liquid) are based strictly on regulatory labeling to maintain product stability and ensure public safety.

Official Storage Requirements

  • Temperature: The medicine must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and protected from extremes of heat, cold, and moisture.
  • Container: Keep the oral liquid in the original container and ensure the cap is tightly closed at all times.
  • Child Safety: All official labeling mandates that the product be kept out of the reach and sight of children in a secured location.

Official Disposal Instructions

Expired or unused Acrotussin should be disposed of by following governmental guidelines. The preferred method is using an authorized drug take-back program. If one is unavailable, the non-flushable medication should be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash, after removing all personal information from the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acrotussin found in:

A-Z Index: